Cargando…

Evaluation of (64)Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates

Objectives: To improve the prognosis of pancreatic cancer, new imaging methods to identify tumor lesions at a size of <1 cm are urgently needed. To approach this clinical issue, we developed a new method to detect small tumor lesions in the pancreas (≥3 mm) by positron emission tomography (PET) u...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Hiroki, Watabe, Tadashi, Igarashi, Chika, Tachibana, Tomoko, Hihara, Fukiko, Waki, Atsuo, Zhang, Ming-Rong, Tashima, Hideaki, Yamaya, Taiga, Ooe, Kazuhiro, Shimosegawa, Eku, Hatazawa, Jun, Yoshida, Sei, Naito, Kenichiro, Kurihara, Hiroaki, Ueno, Makoto, Ito, Kimiteru, Higashi, Tatsuya, Yoshii, Yukie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540406/
https://www.ncbi.nlm.nih.gov/pubmed/34681174
http://dx.doi.org/10.3390/ph14100950
_version_ 1784588979435208704
author Matsumoto, Hiroki
Watabe, Tadashi
Igarashi, Chika
Tachibana, Tomoko
Hihara, Fukiko
Waki, Atsuo
Zhang, Ming-Rong
Tashima, Hideaki
Yamaya, Taiga
Ooe, Kazuhiro
Shimosegawa, Eku
Hatazawa, Jun
Yoshida, Sei
Naito, Kenichiro
Kurihara, Hiroaki
Ueno, Makoto
Ito, Kimiteru
Higashi, Tatsuya
Yoshii, Yukie
author_facet Matsumoto, Hiroki
Watabe, Tadashi
Igarashi, Chika
Tachibana, Tomoko
Hihara, Fukiko
Waki, Atsuo
Zhang, Ming-Rong
Tashima, Hideaki
Yamaya, Taiga
Ooe, Kazuhiro
Shimosegawa, Eku
Hatazawa, Jun
Yoshida, Sei
Naito, Kenichiro
Kurihara, Hiroaki
Ueno, Makoto
Ito, Kimiteru
Higashi, Tatsuya
Yoshii, Yukie
author_sort Matsumoto, Hiroki
collection PubMed
description Objectives: To improve the prognosis of pancreatic cancer, new imaging methods to identify tumor lesions at a size of <1 cm are urgently needed. To approach this clinical issue, we developed a new method to detect small tumor lesions in the pancreas (≥3 mm) by positron emission tomography (PET) using an intraperitoneally (ip)-administered (64)Cu-labeled new anti-epidermal growth factor receptor (EGFR) antibody (encoded as NCAB001), called (64)Cu-NCAB001 ipPET. Methods: NCAB001 was manufactured under cGMP conditions and labeled with (64)Cu. The radiochemical and biological properties of (64)Cu-NCAB001 were evaluated. Tumor uptake of an ip-administered (64)Cu-NCAB001 in mice with orthotopic pancreatic tumor xPA1-DC xenografts was also evaluated. Pharmacokinetics and radiation dosimetry were examined using PET images acquired after the ip administration of (64)Cu-NCAB001 into cynomolgus monkeys with pharmacologic safety monitoring. Results: Radio-chromatography, cell-binding assays, and biodistribution of (64)Cu-NCAB001 in mice were identical to those of our previous data with clinically available cetuximab. Small tumor lesions in the pancreas (≥3 mm) of mice could be identified by (64)Cu-NCAB001 ipPET. The ip administration of (64)Cu-NCAB001 into monkeys was safely conducted using ultrasound imaging. PET images in monkeys showed that ip-administered (64)Cu-NCAB001 was distributed throughout the intraperitoneal cavity for up to 6 h and cleared thereafter. Most of the radioactivity was distributed in the liver and the large intestine. The radioactivity around the pancreas became negligible 24 h after administration. The estimated human effective dose was 0.0174 mSv/MBq. Conclusion: Our data support the initiation of clinical trials of (64)Cu-NCAB001 ipPET to transfer this promising tool for the early diagnosis of pancreatic cancers.
format Online
Article
Text
id pubmed-8540406
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85404062021-10-24 Evaluation of (64)Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates Matsumoto, Hiroki Watabe, Tadashi Igarashi, Chika Tachibana, Tomoko Hihara, Fukiko Waki, Atsuo Zhang, Ming-Rong Tashima, Hideaki Yamaya, Taiga Ooe, Kazuhiro Shimosegawa, Eku Hatazawa, Jun Yoshida, Sei Naito, Kenichiro Kurihara, Hiroaki Ueno, Makoto Ito, Kimiteru Higashi, Tatsuya Yoshii, Yukie Pharmaceuticals (Basel) Article Objectives: To improve the prognosis of pancreatic cancer, new imaging methods to identify tumor lesions at a size of <1 cm are urgently needed. To approach this clinical issue, we developed a new method to detect small tumor lesions in the pancreas (≥3 mm) by positron emission tomography (PET) using an intraperitoneally (ip)-administered (64)Cu-labeled new anti-epidermal growth factor receptor (EGFR) antibody (encoded as NCAB001), called (64)Cu-NCAB001 ipPET. Methods: NCAB001 was manufactured under cGMP conditions and labeled with (64)Cu. The radiochemical and biological properties of (64)Cu-NCAB001 were evaluated. Tumor uptake of an ip-administered (64)Cu-NCAB001 in mice with orthotopic pancreatic tumor xPA1-DC xenografts was also evaluated. Pharmacokinetics and radiation dosimetry were examined using PET images acquired after the ip administration of (64)Cu-NCAB001 into cynomolgus monkeys with pharmacologic safety monitoring. Results: Radio-chromatography, cell-binding assays, and biodistribution of (64)Cu-NCAB001 in mice were identical to those of our previous data with clinically available cetuximab. Small tumor lesions in the pancreas (≥3 mm) of mice could be identified by (64)Cu-NCAB001 ipPET. The ip administration of (64)Cu-NCAB001 into monkeys was safely conducted using ultrasound imaging. PET images in monkeys showed that ip-administered (64)Cu-NCAB001 was distributed throughout the intraperitoneal cavity for up to 6 h and cleared thereafter. Most of the radioactivity was distributed in the liver and the large intestine. The radioactivity around the pancreas became negligible 24 h after administration. The estimated human effective dose was 0.0174 mSv/MBq. Conclusion: Our data support the initiation of clinical trials of (64)Cu-NCAB001 ipPET to transfer this promising tool for the early diagnosis of pancreatic cancers. MDPI 2021-09-23 /pmc/articles/PMC8540406/ /pubmed/34681174 http://dx.doi.org/10.3390/ph14100950 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Matsumoto, Hiroki
Watabe, Tadashi
Igarashi, Chika
Tachibana, Tomoko
Hihara, Fukiko
Waki, Atsuo
Zhang, Ming-Rong
Tashima, Hideaki
Yamaya, Taiga
Ooe, Kazuhiro
Shimosegawa, Eku
Hatazawa, Jun
Yoshida, Sei
Naito, Kenichiro
Kurihara, Hiroaki
Ueno, Makoto
Ito, Kimiteru
Higashi, Tatsuya
Yoshii, Yukie
Evaluation of (64)Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates
title Evaluation of (64)Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates
title_full Evaluation of (64)Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates
title_fullStr Evaluation of (64)Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates
title_full_unstemmed Evaluation of (64)Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates
title_short Evaluation of (64)Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates
title_sort evaluation of (64)cu-labeled new anti-egfr antibody ncab001 with intraperitoneal injection for early pet diagnosis of pancreatic cancer in orthotopic tumor-xenografted mice and nonhuman primates
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540406/
https://www.ncbi.nlm.nih.gov/pubmed/34681174
http://dx.doi.org/10.3390/ph14100950
work_keys_str_mv AT matsumotohiroki evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT watabetadashi evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT igarashichika evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT tachibanatomoko evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT hiharafukiko evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT wakiatsuo evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT zhangmingrong evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT tashimahideaki evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT yamayataiga evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT ooekazuhiro evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT shimosegawaeku evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT hatazawajun evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT yoshidasei evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT naitokenichiro evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT kuriharahiroaki evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT uenomakoto evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT itokimiteru evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT higashitatsuya evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates
AT yoshiiyukie evaluationof64culabelednewantiegfrantibodyncab001withintraperitonealinjectionforearlypetdiagnosisofpancreaticcancerinorthotopictumorxenograftedmiceandnonhumanprimates